STOCK TITAN

Processa Pharmaceuticals, Inc. (PCSA) awards 62,221 RSUs to director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neal James R reported acquisition or exercise transactions in this Form 4 filing.

Processa Pharmaceuticals, Inc. director Neal James R received a grant of 62,221 Restricted Stock Units (RSUs) on July 26, 2026, each representing one share of common stock. The RSUs vested upon grant but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, he holds 67,470 RSUs, stock options for 12,000 shares at $4.96 vesting over three years, and 1,021 common shares, all on a direct-ownership basis. Reported amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.

Positive

  • None.

Negative

  • None.
Insider Neal James R
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units F1, F3 62,221 $0.00 $0.00
holding Stock Options (Right to Buy) F2, F3 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 67,470 shares (Direct); Stock Options (Right to Buy) — 12,000 shares (Direct); Common Stock — 1,021 shares (Direct)
Footnotes (3)
  1. F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
  2. F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
  3. F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
RSUs granted 62,221 units Restricted Stock Units granted to director on July 26, 2026
RSUs outstanding after grant 67,470 units Total Restricted Stock Units held directly after the reported grant
Option exercise price $4.96 per share Exercise price for director stock options over 12,000 underlying shares
Underlying option shares 12,000 shares Common shares underlying stock options held directly after the transaction
Common shares held 1,021 shares Directly owned Processa Pharmaceuticals common stock position
Reverse stock split ratio 1-for-25 Reverse split of common stock effective December 17, 2025
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock options financial
"Stock options vest one-third on the first anniversary date of the grant"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
change of control financial
"distributed until the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider equity award did Processa Pharmaceuticals (PCSA) report for director Neal James R?

Neal James R received a grant of 62,221 Restricted Stock Units (RSUs) on July 26, 2026. Each RSU represents a right to one common share, vesting immediately but distributed later upon termination, six months after grant, change of control, or death.

How many RSUs does Processa Pharmaceuticals (PCSA) director Neal James R now hold?

After the award, Neal James R holds 67,470 Restricted Stock Units directly. These RSUs have vested but will be settled in common stock only upon specified future events, including termination, six months after grant, change of control, or death.

What are the key terms of Neal James R’s stock options reported by PCSA?

He holds stock options over 12,000 shares of common stock with an exercise price of $4.96 per share. The options vest one-third on the first anniversary of the grant, with the remaining two-thirds vesting ratably over the following two years.

How many Processa Pharmaceuticals (PCSA) common shares does Neal James R own directly?

Neal James R directly owns 1,021 shares of common stock in Processa Pharmaceuticals, Inc. This common stock position is in addition to his reported RSU holdings and stock options disclosed in the same insider report.

Were the PCSA insider equity awards to Neal James R made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as relying on a 10b5-1 plan. There is no footnote indicating that the RSU grant or option holdings were executed under a pre-arranged Rule 10b5-1 trading arrangement.

How did Processa Pharmaceuticals’ 1-for-25 reverse stock split affect Neal James R’s reported holdings?

All reported holdings reflect a 1-for-25 reverse stock split effective December 17, 2025. A footnote clarifies that the RSU and option share amounts shown have already been adjusted to account for this reverse split.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Neal James R

(Last)(First)(Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300

(Street)
VERO BEACH FLORIDA 32960

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock1,021D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/26/2026A62,221(1) (1) (1)Common Stock62,221$067,470(3)D
Stock Options (Right to Buy)$4.96 (2) (2)Common Stock12,00012,000(3)D
Explanation of Responses:
1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
/s/ James Neal by John J. Wolfel, as Attorney-in-Fact07/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)